Merck & Co., Inc. (MRK) Shares Sold by Dupont Capital Management Corp

Dupont Capital Management Corp reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 23.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 338,002 shares of the company’s stock after selling 100,703 shares during the period. Dupont Capital Management Corp’s holdings in Merck & Co., Inc. were worth $19,019,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. NewSquare Capital LLC raised its holdings in Merck & Co., Inc. by 728.3% during the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock worth $115,000 after purchasing an additional 13,014 shares in the last quarter. Balentine LLC raised its holdings in Merck & Co., Inc. by 1.0% during the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after purchasing an additional 20 shares in the last quarter. WealthTrust Arizona LLC raised its holdings in Merck & Co., Inc. by 103.7% during the fourth quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock worth $140,000 after purchasing an additional 1,270 shares in the last quarter. Risk Paradigm Group LLC raised its holdings in Merck & Co., Inc. by 748.1% during the second quarter. Risk Paradigm Group LLC now owns 2,256 shares of the company’s stock worth $145,000 after purchasing an additional 1,990 shares in the last quarter. Finally, QCI Asset Management Inc. NY raised its holdings in Merck & Co., Inc. by 10.6% during the second quarter. QCI Asset Management Inc. NY now owns 2,494 shares of the company’s stock worth $160,000 after purchasing an additional 239 shares in the last quarter. 74.63% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

Several research analysts have issued reports on MRK shares. SunTrust Banks raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and upped their price target for the company from $54.00 to $72.00 in a report on Tuesday, January 16th. BMO Capital Markets set a $65.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a report on Wednesday, February 21st. Leerink Swann dropped their price target on Merck & Co., Inc. from $67.00 to $66.00 and set a “market perform” rating on the stock in a report on Wednesday, February 14th. Jefferies Group reaffirmed a “hold” rating and issued a $55.00 price target on shares of Merck & Co., Inc. in a report on Tuesday, January 16th. Finally, ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $66.47.

NYSE:MRK traded down $1.17 during trading hours on Friday, reaching $53.36. The company’s stock had a trading volume of 12,500,816 shares, compared to its average volume of 11,017,954. The stock has a market capitalization of $143,868.70, a PE ratio of 13.41, a P/E/G ratio of 2.25 and a beta of 0.78. Merck & Co., Inc. has a one year low of $52.83 and a one year high of $66.41. The company has a current ratio of 1.33, a quick ratio of 1.06 and a debt-to-equity ratio of 0.62.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. The firm had revenue of $10.43 billion during the quarter, compared to analysts’ expectations of $10.48 billion. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. Merck & Co., Inc.’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 earnings per share. sell-side analysts forecast that Merck & Co., Inc. will post 4.16 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, April 6th. Shareholders of record on Thursday, March 15th were given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date was Wednesday, March 14th. Merck & Co., Inc.’s dividend payout ratio is 48.24%.

In other news, insider Weir Mirian M. Graddick sold 5,000 shares of the company’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $58.00, for a total transaction of $290,000.00. Following the completion of the transaction, the insider now owns 101,484 shares of the company’s stock, valued at $5,886,072. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $3,697,800.00. Following the transaction, the insider now directly owns 101,484 shares of the company’s stock, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,500 shares of company stock valued at $5,026,025. Company insiders own 0.25% of the company’s stock.

WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/merck-co-inc-mrk-shares-sold-by-dupont-capital-management-corp.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply